American Heart Journal

Article	Citations
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design	134
Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coro	106
Extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock - Design and rationale of the ECLS-SHOCK trial	85
Clinical applications of machine learning in the diagnosis, classification, and prediction of heart failure	84
A current review of COVID-19 for the cardiovascular specialist	81
Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance	79
Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes—Systematic review and meta-analysis of randomized placebo-controlled trials	73
Impact of the COVID-19 pandemic on patterns of outpatient cardiovascular care	69
Precision medicine in distinct heart failure phenotypes: Focus on clinical epigenetics	68
Decrease in acute coronary syndrome presentations during the COVID-19 pandemic in upstate New York	66
Shock in the cardiac intensive care unit: Changes in epidemiology and prognosis over time	63
Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study	63
Admission diagnosis and mortality risk prediction in a contemporary cardiac intensive care unit population	62
Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial	62
Rationale and design of a large population study to validate software for the assessment of atrial fibrillation from data acquired by a consumer tracker or smartwatch: The Fitbit heart study	58
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficac	58
Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart	58
A randomized controlled trial of lung ultrasound-guided therapy in heart failure (CLUSTER-HF study)	57
Impact of COVID-19 pandemic on patients with ST-segment elevation myocardial infarction: Insights from a British cardiac center	57
Thrombosis in hospitalized patients with viral respiratory infections versus COVID-19	53
Rationale and design of the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR) trial	51
Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and	48
Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial	48
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial	47
To Adjust or Not to Adjust: The Role of Different Covariates in Cardiovascular Observational Studies	43

Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits	42
The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disea	42
RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis	42
Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study	41
Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)	41
Trends of blood pressure control in the U.S. during the COVID-19 pandemic	40
Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial	40
Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update	37
Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease	37
Plasma trimethylamine N-oxide (TMAO) levels predict future risk of coronary artery disease in apparently healthy individuals in the EPIC-Norfolk prospective population study	35
Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study	35
Cardiovascular comorbidities, cardiac injury, and prognosis of COVID-19 in New York City	33
Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy	33
Modifiable lifestyle factors and heart failure: A Mendelian randomization study	32
Quantitative flow ratio–guided strategy versus angiography-guided strategy for percutaneous coronary intervention: Rationale and design of the FAVOR III China trial	32
North American COVID-19 ST-Segment-Elevation Myocardial Infarction (NACMI) registry: Rationale, design, and implications	31
Diagnosis, prevention, and management of delirium in the intensive cardiac care unit	31
Transcatheter InterAtrial Shunt Device for the treatment of heart failure: Rationale and design of the pivotal randomized trial to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure I	30
Smartphone-based application to improve medication adherence in patients after surgical coronary revascularization	29
Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease	29
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE	28
Complex high-risk and indicated percutaneous coronary intervention for stable angina: Does operator volume influence patient outcome?	28
Financial burden, distress, and toxicity in cardiovascular disease	28
Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF): A cluster randomized trial of a computerized clinical decision support tool	27
Reducing disparities in adverse pregnancy outcomes in the United States	27
Periodontal Disease, Atrial Fibrillation and Stroke	26
Performance of diagnostic criteria in patients clinically judged to have cardiac sarcoidosis: Is it time to regroup?	26
Associations between anthropometric indices and outcomes of congenital heart operations in infants and young children: An analysis of data from the Society of Thoracic Surgeons Database	25
Epidemiology of in-hospital cardiac arrest complicating non–ST-segment elevation myocardial infarction receiving early coronary angiography	25
Rationale and design of a randomized clinical trial comparing safety and efficacy of myval transcatheter heart valve versus contemporary transcatheter heart valves in patients with severe symptomatic	25
Physiology-guided revascularization versus optimal medical therapy of nonculprit lesions in elderly patients with myocardial infarction: Rationale and design of the FIRE trial	24
Association of gut-related metabolites with outcome in acute heart failure	24
Trends in first-time hospitalization, management, and short-term mortality in acute myocardial infarction–related cardiogenic shock from 2005 to 2017: A nationwide cohort study	24
Trends in hospitalizations for heart failure, acute myocardial infarction, and stroke in the United States from 2004 to 2018	24
A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry	24
Expanding the clinical and genetic spectrum of ALPK3 variants: Phenotypes identified in pediatric cardiomyopathy patients and adults with heterozygous variants	24
The IMPact on Revascularization Outcomes of intraVascular ultrasound-guided treatment of complex lesions and Economic impact (IMPROVE) trial: Study design and rationale	24
Evaluation of safety and efficacy of coronary intravascular lithotripsy for treatment of severely calcified coronary stenoses: Design and rationale for the Disrupt CAD III trial	23
Improved outcomes in patients with severely depressed LVEF undergoing percutaneous coronary intervention with contemporary practices	23
Rationale and methods of the Advanced R2Eperfusion STrategies for Refractory Cardiac Arrest (ARREST) trial	23
Association of postoperative complications and outcomes following coronary artery bypass grafting	23
Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study	23
Cardiac pathology 6 months after hospitalization for COVID-19 and association with the acute disease severity	23
Study protocol and baseline characteristics of Randomized trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy–Statin and Eicosapentaenoic Acid: RESPECT-EPA, the combination of	22
High-intensity endurance training is associated with left atrial fibrosis	22
Association between ambient air pollution and county-level cardiovascular mortality in the United States by social deprivation index	22
The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic he	21
Percutaneous coronary intervention or coronary artery bypass graft surgery for left main coronary artery disease: A meta-analysis of randomized trials	21
Catheter ablation for persistent atrial fibrillation: A multicenter randomized trial of pulmonary vein isolation (PVI) versus PVI with posterior left atrial wall isolation (PWI) - The CAPLA study	21
Out-of-hospital cardiac arrest: A systematic review of current risk scores to predict survival	21

Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes	20
Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib	20
A randomized ablation-based atrial fibrillation rhythm control versus rate control trial in patients with heart failure and high burden atrial fibrillation: The RAFT-AF trial rationale and design	19
Adherence with lipid screening guidelines in standard- and high-risk children and adolescents	19
Batch enrollment for an artificial intelligence-guided intervention to lower neurologic events in patients with undiagnosed atrial fibrillation: rationale and design of a digital clinical trial	19
Paclitaxel-related balloons and stents for the treatment of peripheral artery disease: Insights from the Food and Drug Administration 2019 Circulatory System Devices Panel Meeting on late mortality	19
Outcomes in Kawasaki disease patients with coronary artery abnormalities at admission	19
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting sten	19
Rationale and design of the SMall Annuli Randomized To Evolut or SAPIEN Trial (SMART Trial)	19
Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation	19
Internet search volume for chest pain during the COVID-19 pandemic	18
Sarcopenia and health-related quality of life in older adults after transcatheter aortic valve replacement	18
Sociodemographic differences in utilization and outcomes for temporary cardiovascular mechanical support in the setting of cardiogenic shock	18
Telemedicine in myocarditis: Evolution of a mutidisciplinary “disease unit” at the time of COVID-19 pandemic	18
Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial	17
Mild sleep restriction increases 24-hour ambulatory blood pressure in premenopausal women with no indication of mediation by psychological effects	17
Neighborhood education status drives racial disparities in clinical outcomes in PPCM	17
Coarctation of aorta is associated with left ventricular stiffness, left atrial dysfunction and pulmonary hypertension	17
A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making	17
The NHLBI Study on Long-terM OUtcomes after the Multisystem Inflammatory Syndrome In Children (MUSIC): Design and Objectives	17
Cardiac remodeling after large ST-elevation myocardial infarction in the current therapeutic era	17
Convergence of Epicardial and Endocardial RF Ablation for the Treatment of Symptomatic Persistent AF (CONVERGE Trial): Rationale and design	17
Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial	16
Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optic	16
Sex disparities in patients with symptomatic severe aortic stenosis	16
Radial versus femoral artery access for percutaneous coronary artery intervention in patients with acute myocardial infarction and multivessel disease complicated by cardiogenic shock: Subanalysis fro	16
Impact of COVID-19 epidemic on coronary care unit accesses for acute coronary syndrome in Veneto region, Italy	16
Behavioral Nudges as Patient Decision Support for Medication Adherence: The ENCOURAGE Randomized Controlled Trial	16
Gender differences in industry payments among cardiologists	16
EMERGEncy versus delayed coronary angiogram in survivors of out-of-hospital cardiac arrest with no obvious non-cardiac cause of arrest: Design of the EMERGE trial	16
Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial	16
Incidence, underlying conditions, and outcomes of patients receiving acute renal replacement therapies in tertiary cardiac intensive care units: An analysis from the Critical Care Cardiology Trials Ne	16
Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and prese	16
Depressive hypertension: A proposed human endotype of brain/gut microbiome dysbiosis	15
No-touch saphenous vein grafts in coronary artery surgery (SWEDEGRAFT): Rationale and design of a multicenter, prospective, registry-based randomized clinical trial	15
Distal Evaluation of Functional performance with Intravascular sensors to assess the Narrowing Effect—combined pressure and Doppler FLOW velocity measurements (DEFINE-FLOW) trial: Rationale and trial	15
iPhone App compared with standard blood pressure measurement –The iPARR trial	15
Early intra-aortic balloon pump in acute decompensated heart failure complicated by cardiogenic shock: Rationale and design of the randomized Altshock-2 trial	15
Sacubitril/valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: A randomized, double-blind, active-controlled study	15
Biodegradable polymer sirolimus-eluting stents vs durable polymer everolimus-eluting stents in patients undergoing percutaneous coronary intervention: A meta-analysis of individual patient data from 5	14
Noninvasive echocardiographic cardiac power output predicts mortality in cardiac intensive care unit patients	14
Early rehabilitation in older patients hospitalized with acute decompensated heart failure: A retrospective cohort study	14
Atrial fibrillation detection using ambulatory smartwatch photoplethysmography and validation with simultaneous holter recording	14
TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: The TROUPER trial	14
Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis	14
Ultra-low-dose quadruple combination blood pressure–lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol	14
Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: Results from the longitudinal global discover study	14
Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTl	14
Cardiac safety research consortium “shock II” think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock	14
The Second Strategic Reperfusion Early After Myocardial Infarction (STREAM-2) study optimizing pharmacoinvasive reperfusion strategy in older ST-elevation myocardial infarction patients	13
The trial to assess chelation therapy 2 (TACT2): Rationale and design	13
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline chara	13
Prognostic value of brain natriuretic peptides in patients with pulmonary arterial hypertension: A systematic review and meta-analysis	13
Trends in transcatheter and surgical aortic valve replacement in the United States, 2008-2018	13
COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial	13
Cardiovascular procedural deferral and outcomes over COVID-19 pandemic phases: A multi-center study	13
Underweight is associated with inferior short and long-term outcomes after MitraClip implantation: Results from the German TRAnscatheter mitral valve interventions (TRAMI) registry	13
Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice dai	13
Incidence of acute coronary syndrome during national lock-down: Insights from nationwide data during the Coronavirus disease 2019 (COVID-19) pandemic	13
Acute myocardial infarction under-diagnosis and mortality in a Tanzanian emergency department: A prospective observational study	13
Clinical predictors of left ventricular involvement in arrhythmogenic right ventricular cardiomyopathy	13
Patient-centered contrast thresholds to reduce acute kidney injury in high-risk patients undergoing percutaneous coronary intervention	13
Treatment strategies and subsequent changes in the patient-reported quality-of-life among elderly patients with atrial fibrillation	13
Outcome impact of different tranexamic acid regimens in cardiac surgery with cardiopulmonary bypass (OPTIMAL): Rationale, design, and study protocol of a multicenter randomized controlled trial	13
The impact of left atrium size on selection of the pulmonary vein isolation method for atrial fibrillation: Cryoballoon or radiofrequency catheter ablation	13
Randomized evaluation of vessel preparation with orbital atherectomy prior to drug-eluting stent implantation in severely calcified coronary artery lesions: Design and rationale of the ECLIPSE trial	13
Randomized controlled trial of perhexiline on regression of left ventricular hypertrophy in patients with symptomatic hypertrophic cardiomyopathy (RESOLVE-HCM trial)	13
Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)	13
The prospective randomized trial of the optimal evaluation of cardiac symptoms and revascularization: Rationale and design of the PRECISE trial	13
Community-based, cluster-randomized pilot trial of a cardiovascular mHealth intervention: Rationale, design, and baseline findings of the FAITH! Trial	13
Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 w	13
A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19	12
Distal versus conventional radial access for coronary angiography and intervention: Design and rationale of DISCO RADIAL study	12
The association of healthcare disparities and patient-specific factors on clinical outcomes in peripheral artery disease	12
Future research prioritization in cardiac resynchronization therapy	12
Text messages for primary prevention of cardiovascular disease: The TextMe2 randomized clinical trial	12
Longitudinal study of anthropometry in Fontan survivors: Pediatric Heart Network Fontan study	12
The cardiac intensive care unit and the cardiac intensivist during the COVID-19 surge in New York City	12
A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial	12
Impact of chronic total occlusion and revascularization strategy in patients with infarct-related cardiogenic shock: A subanalysis of the culprit-shock trial	12

Temporal trends in utilization of transcatheter aortic valve replacement and patient characteristics: A nationwide study	12
Move more – be happier? physical activity and health-related quality of life in children with congenital heart disease	12
Design and Rationale of a Phase 2 Study of NeurOtoxin (Botulinum Toxin Type A) for the PreVention of Post-Operative Atrial Fibrillation – The NOVA Study	12
Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale	12
Rationale and Design of the Groningen Intervention Study for the Preservation of Cardiac Function with Sodium Thiosulfate after St-segment Elevation Myocardial Infarction (GIPS-IV) trial	12
Rationale and design of a cluster-randomized pragmatic trial aimed at improving use of guideline directed medical therapy in outpatients with heart failure: PRagmatic trial of messaging to providers a	12
Nationwide cardiovascular disease admission rates during a second COVID-19 lockdown	12
Rationale and design of a prospective, randomized, controlled, multicenter study to evaluate the safety and efficacy of transcatheter heart valve replacement in female patients with severe symptomatic	12
Discrepancy in recognition of symptom burden among patients with atrial fibrillation	12
Long-term prognostic outcomes and implication of oral anticoagulants in patients with new-onset atrial fibrillation following st-segment elevation myocardial infarction	12
Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with ora	12
Comparison of intravascular ultrasound-guided with angiography-guided double kissing crush stenting for patients with complex coronary bifurcation lesions: Rationale and design of a prospective, rando	12
Overcoming underpowering: Trial simulations and a global rank end point to optimize clinical trials in children with heart disease	12
Rationale and design of the Flow Evaluation to Guide Revascularization in Multivessel ST-Elevation Myocardial Infarction (FLOWER-MI) trial	12
Helicobacter pylori screening in clinical routine during hospitalization for acute myocardial infarction	11
High-Sensitivity Cardiac Troponin—Optimizing the Diagnosis of Acute Myocardial Infarction/Injury in Women (CODE-MI): Rationale and design for a multicenter, stepped-wedge, cluster-randomized trial	11
COVID-19 and the cardiovascular system: A review of current data, summary of best practices, outline of controversies, and illustrative case reports	11
Potent P2Y12 inhibitors versus Clopidogrel in elderly patients with acute coronary syndrome: Systematic review and meta-analysis	11
Cryoballoon catheter ablation versus antiarrhythmic drugs as a first-line therapy for patients with paroxysmal atrial fibrillation: Rationale and design of the international Cryo-FIRST study	11
Cardiac resynchronization therapy improves the ventricular function of patients with Fontan physiology	11
China Tongxinluo Study for myocardial protection in patients with Acute Myocardial Infarction (CTS-AMI): Rationale and design of a randomized, double-blind, placebo-controlled, multicenter clinical tr	11
Transcatheter mitral valve repair for inotrope dependent cardiogenic shock – Design and rationale of the CAPITAL MINOS trial	11
Comparison of a new 3-item self-reported measure of adherence to medication with pharmacy claims data in patients with cardiometabolic disease	11
Rationale and design for the myocardial ischemia and transfusion (MINT) randomized clinical trial	11
Distinct triglyceride-glucose trajectories are associated with different risks of incident cardiovascular disease in normal-weight adults	11
P2Y12 inhibitor monotherapy versus aspirin monotherapy after short-term dual antiplatelet therapy for percutaneous coronary intervention: Insights from a network meta-analysis of randomized trials	11
Rationale and design of the MULTISTARS AMI Trial: A randomized comparison of immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multives	11
Specificity of administrative coding for older adults with acute heart failure hospitalizations	11
Rationale and design of the TAILOR-PCI digital study: Transitioning a randomized controlled trial to a digital registry	11
Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above: Rationale and design of a real-world pragmatic	11
Association between levosimendan, postoperative AKI, and mortality in cardiac surgery: Insights from the LEVO-CTS trial	11
Non-vitamin K antagonist oral anticoagulants in very elderly east Asians with atrial fibrillation: A nationwide population-based study	11
Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)	11
TAVR for low-flow, low-gradient aortic stenosis: Prognostic impact of aortic valve calcification	11
Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction—Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA	11
Initial rhythm control with cryoballoon ablation vs drug therapy: Impact on quality of life and symptoms	10
Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19)	10
Whole genome sequencing in transposition of the great arteries and associations with clinically relevant heart, brain and laterality genes	10
Cardiac transplantation outcomes in patients with amyloid cardiomyopathy	10
Individuals aged 1-64 years with documented congenital heart defects at healthcare encounters, five U.S. surveillance sites, 2011-2013	10
Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity?	10
Cost-effectiveness of combined catheter ablation and left atrial appendage closure for symptomatic atrial fibrillation in patients with high stroke and bleeding risk	10
One-year outcome after percutaneous coronary intervention in nonagenarians: Insights from the J-PCI OUTCOME registry	10
Primary left ventricular unloading with delayed reperfusion in patients with anterior ST-elevation myocardial infarction: Rationale and design of the STEMI-DTU randomized pivotal trial	10
Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic	10
Optimal antiplatelet therapy for prevention of gastrointestinal injury evaluated by ANKON magnetically controlled capsule endoscopy: Rationale and design of the OPT-PEACE trial	10
Are cost advantages from a modern Indian hospital transferable to the United States?	10
Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized pa	10
Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations	10
Menopausal age and left ventricular remodeling by cardiac magnetic resonance imaging among 14,550 women	10
Transcatheter aortic valve replacement for patients with severe bicuspid aortic stenosis	10
Modified design of stimulation of the left ventricular endocardium for cardiac resynchronization therapy in nonresponders, previously untreatable and high-risk upgrade patients (SOLVE-CRT) trial	9
Defect-free care trends in the Paul Coverdell National Acute Stroke Program, 2008-2018	9
Aortic valve neocuspidization using the Ozaki technique: A meta-analysis of reconstructed patient-level data	9
Comparison of anticoagulation with left atrial appendage closure after atrial fibrillation ablation: Rationale and design of the OPTION randomized trial	9
Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis	9
Virtual AppLication-supported Environment To INcrease Exercise (VALENTINE) during cardiac rehabilitation study: Rationale and design	9
Impact of salt substitute and stepwise reduction of salt supply on blood pressure in residents in senior residential facilities: Design and rationale of the DECIDE-Salt trial	9
Left atrial appendage occlusion vs novel oral anticoagulation for stroke prevention in atrial fibrillation: rationale and design of the multicenter randomized occlusion-AF trial	9
Short-term PM2.5 exposure and early-readmission risk: a retrospective cohort study in North Carolina heart failure patients	9
Danish-German cardiogenic shock trial—DanGer shock: Trial design update	9
Acute kidney injury after radial or femoral artery access in ST-segment elevation myocardial infarction: AKI-SAFARI	9
Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) – A phase III study	9
Rationale and design of BROKEN-SWEDEHEART: a registry-based, randomized, parallel, open-label multicenter trial to test pharmacological treatments for broken heart (takotsubo) syndrome	9
Epidemiologic trends and risk factors associated with the decline in mortality from coronary heart disease in the United States, 1990-2019	9
Nationwide Utilization of Danish Government Electronic letter system for increasing inFLUenza vaccine uptake (NUDGE-FLU): Study protocol for a nationwide randomized implementation trial	9
Long-term outcomes of arrhythmia and distinct electrophysiological features in congenitally corrected transposition of the great arteries in an Asian cohort	9
Comparative risk of dementia among patients with atrial fibrillation treated with catheter ablation versus anti-arrhythmic drugs	9
Percutaneous complete revascularization strategies using sirolimus-eluting biodegradable polymer-coated stents in patients presenting with acute coronary syndrome and multivessel disease: Rationale an	9
A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response	9
Expansion of transcatheter aortic valve replacement in the United States	9
Days alive out of hospital in heart failure: Insights from the PARADIGM-HF and CHARM trials	9
Cardiovascular risk factor profiles in North and South Indian and Pakistani Americans: The MASALA Study	9
Incidence of sudden cardiac arrest and sudden cardiac death after unstable angina pectoris and myocardial infarction	9
Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE)	9
Harmonization of the definition of sudden cardiac death in longitudinal cohorts of the European Sudden Cardiac Arrest network – towards Prevention, Education, and New Effective Treatments (ESCAPE-NET)	9
Statins and atherosclerotic cardiovascular outcomes in patients on incident dialysis and with atherosclerotic heart disease	9
PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial	9
Comparison between ticagrelor and clopidogrel on myocardial blood flow in patients with acute coronary syndrome, using 13 N-ammonia positron emission tomography	9
Performance of the ESC 0/2h-algorithm using high-sensitivity cardiac troponin I in the early diagnosis of myocardial infarction	9
Prognostic value of myocardial fibrosis on cardiac magnetic resonance imaging in patients with ischemic cardiomyopathy: A systematic review	8
Potential impact of the steroid hormone, vitamin D, on the vasculature	8
The pediatric heart network's study on long-term outcomes of children with HLHS and the impact of Norwood Shunt type in the single ventricle reconstruction trial cohort (SVRIII): Design and adaptation	8
Growth differentiation factor-15 is a biomarker for all-cause mortality but less evident for cardiovascular outcomes: A prospective study	8
National Heart, Lung, and Blood Institute cardiovascular clinical trial perspective	8
Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program	8
Comparing a strategy of sirolimus-eluting balloon treatment to drug-eluting stent implantation in de novo coronary lesions in all-comers: Design and rationale of the SELUTION DeNovo Trial	8
Beliefs, risk perceptions, and lipid management among patients with and without diabetes: Results from the PALM registry	8
Cardiogenic shock complicating non-ST-segment elevation myocardial infarction: An 18-year study	8
Sinus of Valsalva Dimension and Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation	8
Sedentary time and peripheral artery disease: The Hispanic Community Health Study/Study of Latinos	8
Outcomes following cardioversion for patients with cardiac amyloidosis and atrial fibrillation or atrial flutter	8
Sarcopenia in cardiac surgery: Dual X-ray absorptiometry study from the McGill frailty registry	8
Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery disease	8
Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial	8